LGND
LigandยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
LGND Profile
Ligand Pharmaceuticals Incorporated
A company that develops pharmaceuticals in the areas of oncology, central nervous system, inflammation, and blood disorders
555 Heritage Drive, Suite 200, Jupiter Florida 33458
--
Ligand Pharmaceuticals Incorporated was incorporated in Delaware in 1987 and is a biopharmaceutical company. The company's business model is to develop or acquire income-generating assets and integrate them into the cost structure of a lean enterprise. The company's goal is to create a sustainable and profitable business to generate shareholder value. Since the company's business model is based on cooperating with other pharmaceutical companies to commercialize and sell assets, a lot of the company's revenue comes from related royalties provided by partners. Recognizing the importance of drug reformulation in the pharmaceutical industry, the company added the CAPTISOL project to its technology investment in 2011. CAPTISOL is a powerful formulation technology with five U.S. Food and Drug Administration approved products, including Pfizer's VFEND IV and Baxter International's Nexterone, as well as several other partner programs that are in clinical use. Compared with other companies in the same industry, the company has formed one of the largest diversified asset portfolios in the industry, which can generate significant returns in the future. Therapeutics developed in the portfolio can address many unaddressed gaps in medical needs, including hepatitis, muscle atrophy, Alzheimer's disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis, and osteoporosis.
